Revolutionary 'Immune Reset' Therapy Puts Severe Lupus Patients into Remission
In a groundbreaking UK trial, a single dose of genetically modified CAR T-cells has effectively cured five patients of severe lupus, offering hope for a permanent end to lifelong autoimmune medication.
By Factlen Editorial Team
- Medical Researchers
- Focuses on the targeted mechanism of CD19 depletion and the need for long-term data to confirm durability.
- Patient Advocacy
- Highlights the life-changing quality-of-life improvements and the escape from toxic, lifelong immunosuppressants.
- Health Systems
- Views the breakthrough through the lens of treatment paradigms, noting the shift from chronic management to potential single-dose cures.
What's not represented
- · Health insurance providers evaluating the high cost of cellular therapies
- · Patients in developing nations without access to advanced genetic medicine
Why this matters
Lupus affects over 5 million people globally, mostly women, and is currently managed with lifelong, broad-spectrum immunosuppressants that leave patients vulnerable to infections. A single-dose therapy that permanently resets the immune system could transform autoimmune care from symptom management to an actual cure.
More in health
See all 122 stories →CAR-T Therapy
CAR-T Cell Therapy Puts Severe Lupus Into Remission in UK Trial
7 sources
Autoimmune Research
CAR-T Cell Therapy Induces Drug-Free Remission in Severe Lupus Patients
6 sources
Medical Breakthrough
Pioneering 'Immune Reset' Therapy Puts Severe Lupus Patients Into Remission
8 sources
Longevity Science
The Emerging Science of VO2 Max and Grip Strength as Primary Predictors of Men's Longevity
7 sources
Every angle. Every day.
Get health stories with full source coverage and perspective breakdowns delivered to your inbox.